Background: Hypertension is a common, non-communicable disorder of public health significance. Abnormalities in haemostasis and blood rheology have been linked to target organ damage (TOD) in hypertension. Microalbuminuria (MA) is an independent predictor of TOD.
Methods: A cross-sectional study was carried out among 107 consecutively recruited hypertensives attending the Cardiology Clinic at ABUTH, Zaria, Nigeria. Complete blood counts, haemostatic screening tests and microalbuminuria assay were performed on blood and urine specimens.
Results: The mean age of participants was 50.2±11.3 years and 59.3±18.2 years for females and males respectively with a female predominance (91/107; 85%). The frequencies of abnormal platelet counts, prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, D-dimer and MA were 15%, 57%, 54.2%, 64.5%, 100%, 25.2%, and 41% respectively. Participants with poor BP control had an increased risk of derangements in aPTT and platelet counts (OR = 1.4, 1.4) but there was no significant difference in means with BP for aPTT, fibrinogen, and platelets (p = 0.517, 0.257 and 0.525 respectively). The impact of the duration of hypertension was shown in D-dimer levels up to 10 years. Participants on ARB/ACEI- containing regimens showed a higher risk of derangement in TT, aPTT, PT and D-dimer in contrast to platelet counts (OR = 0.96, p = 0.836). Haemostatic parameters showed weakly positive, statistically significant correlation on regression analysis.
Conclusion: There is a high prevalence of, and positive correlation between haemostatic abnormalities and MA among hypertensives in Northern Nigeria. Abnormal haemostatic screening tests may indicate MA and increased risk of TOD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.